AIM ImmunoTech Inc. AIM
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $9.00 (+3552.6% upside)
Key Stats
- Today's Range
- $0.23 – $0.26
- 50-Day Range
- $0.19 – $0.66
- 52-Week Range
- $0.19 – $20.33
- Volume
- 1.90 million shs
- Average Volume
- 1.18 million shs
- Market Cap
- $6.69 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.57
- Price / Sales
- —
Short Interest
- Short Interest
- 0.32%
- Days to Cover
- 1.69
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Related Stocks
Compare head-to-head: AIM vs AMGN·AIM vs HALO·AIM vs KYMR·AIM vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.